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 •  This case demonstrates a deadly combination of inappropriate SGLT-2 inhibitor use causing decreased serum glucose levels in a 
MODY type 2 patient resulting in euglycemic DKA
 •  MODY Type 2 results from a defective glucokinase enzyme, therefore increased serum glucose levels are required to trigger insulin 
secretion
 •  Patients with MODY Type 2 often present with mild fasting hyperglycemia, which is required to stimulate insulin secretion
 •  In this case, empagliflozin resulted in decreased serum glucose and increased glucosuria. As a result, the body’s demands for insulin 
were higher than the amount of insulin being secreted due to defective glucokinase enzyme, inducing DKA.
42 year old female with mature onset diabetes of the young (MODY) type 2 
presented to the emergency room with complaints of nausea, vomiting and 
epigastric abdominal pain worsening over four days. She was diagnosed 
with gestational DM at age 34 and post-partum was unsuccessfully treated 
with a variety of oral medications. She underwent testing which revealed a 
glucokinase mutation consistent with MODY type 2. Recently, she was started 
on empagliflozin-linagliptin in addition to a diet of less than 60 grams of 
carbohydrates per day. On admission, imaging was unrevealing, and she was 
diagnosed with gastroenteritis. Her serum glucose was 106 mg/dL, potassium 
was 4.6 mmol/L, bicarbonate was 21 mmol/L, anion gap was 14, and lipase 
was normal. Urinalysis revealed glucose of 500 mg/dL, ketones > 160 mg/dL, 
and specific gravity >1.030. Venous blood gas revealed metabolic acidosis. Beta 
hydroxybutyrate was 2.71 mmol/L. The patient was diagnosed with euglycemic 
DKA. Endocrinology discontinued empagliflozin, emphasizing that the only 
treatment required for MODY type 2 is diet restriction. Her symptoms improved, 
labs normalized, and she was discharged.
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 •  Diabetic ketoacidosis (DKA) occurs when the body’s requirements for insulin are higher than the insulin available for use, 
resulting in lipolysis, ketogenesis, and ketoacidosis
 •  DKA is classically associated with Type 1 diabetes mellitus (DM), but can occur in any patient with diabetes
 •  Euglycemic DKA is defined by ketosis, metabolic acidosis, and a blood glucose level less than 200 mg/dL
 •  Euglycemic DKA is concerning as it can be easily misdiagnosed and mistreated
 • Few cases have demonstrated a possible relationship between empagliflozin and euglycemic DKA
 •  Empagliflozin is a sodium glucose co-transporter (SLGT-2) inhibitor in the proximal convoluted tubule of the kidney to reduce 
reabsorbed filtered glucose, resulting in decreased serum glucose levels.
Figure:  Demonstration of the cascade of clinical events and metabolic 
changes that contribute sequentially to progressive clinical deterioration 
and develoment of full-blown episodes of euDKA. BG, blood glucose; CHO, 
carbohydrate; TGs, triglycerides.
Lehigh Valley Health Network, Allentown, Pennsylvania
Euglycemic DKA in MODY Patient: Empagliflozin to Blame
Angela Magdaleno, DO, Sandhya Venkataraman, DO and Gretchen Perilli, MD











Worsened by ↓ 




↓ caloric intake, 
volume 
depletion









 Table 1 - Genetic and Clinical Characteristics of MODY Subgroups
 MODY 1 MODY 2 MODY 3 MODY 4 MODY 5
Genetics HNF-4α (20q13) Glucokinase (7p15) HNF-1α (12q24) IPF-1 (13q12) HNF-1ß (17cen-q21)
Prevalence 5% 15% 70% < 1% 2%
Severity Progressive IGT Mild,stable hyperglycemia Progressive IGT Progressive IGT Progressive IGT
Onset 12-35 years Birth 12-28 years 14-40 years 12-28 years
Microvascular Complications + Rare + + +renal
Treatment Progressive need Pregnancy Progressive need Progressive need Progressive need
